High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 10, 2012, Pages 1181-1189

  Van Egmond, R ^a   Chin, P ^a   Zhang, M ^b   Sies, C W ^c   Barclay, M L ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; MERCAPTOPURINE; METHYLMERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; COMPARATIVE STUDY; DRUG RESISTANCE; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SYNTHESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NEW ZEALAND; PATIENT IDENTIFICATION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; AZATHIOPRINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE; ERYTHROCYTE MEMBRANE; FEMALE; GENOTYPE; GUANINE NUCLEOTIDES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; STATISTICS AS TOPIC; THIOGUANINE; THIONUCLEOTIDES;

EID: 84859918881     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05084.x     Document Type: Article

References (38)

1. Prefontaine E, Macdonald JK, Sutherland LR,. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010; 6: CD000545.
2. Pearson DC, May GR, Fick GH, Sutherland LR,. Azathioprine and 6-mercaptopurine in Crohn disease-a meta analysis. Ann Intern Med 1995; 123: 132-42.
3. Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollõn F,. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009; 30: 126-37.
4. Bouhnik Y, Lemann M, Mary JY, et al,. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-9. (Pubitemid 26035245)
5. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9. (Pubitemid 34638866)
6. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA,. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13: 563-7. (Pubitemid 39214035)
7. Jharap B, Seinen ML, de Boer NK, et al,. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-9.
8. Dubinsky MC, Lamothe S, Yang HY, et al,. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13. (Pubitemid 30171620)
9. Cuffari C, Hunt S, Bayless T,. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6. (Pubitemid 32378583)
10. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD,. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
11. Schaeffeler E, Fischer C, Brockmeier D, et al,. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-17. (Pubitemid 38971231)
12. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S,. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 331-42. (Pubitemid 43972901)
13. Lennard L, Van Loon JA, Weinshilboum RM,. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54. (Pubitemid 19219950)
14. Colombel JF, Ferrari N, Debuysere H, et al,. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30. (Pubitemid 30346978)
15. Black AJ, McLeod HL, Capell HA, et al,. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-8. (Pubitemid 28507145)
16. Schwab M, Schaffeler E, Marx C, et al,. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36. (Pubitemid 34918619)
17. Gearry RB, Barclay ML, Burt MJ, et al,. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 395-400. (Pubitemid 37070237)
18. Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K,. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1105-12. (Pubitemid 39536400)
19. Dubinsky MC, Yang H, Hassard PV, et al,. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15. (Pubitemid 34267273)
20. Gearry RB, Barclay ML, Roberts RL, et al,. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005; 35: 580-5. (Pubitemid 41564403)
21. Derijks LJ, Gilissen LP, Engels LG, et al,. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-18. (Pubitemid 38703020)
22. Sparrow MP, Hande SA, Friedman S, et al,. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22: 441-6. (Pubitemid 41248111)
23. Gardiner SJ, Gearry RB, Burt MJ, et al,. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol 2011; 26: 49-54.
24. Ansari A, Elliott T, Baburajan B, et al,. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 734-41.
25. Ansari A, Hassan C, Duley J, et al,. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
26. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM,. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2: 410-7. (Pubitemid 38561239)
27. Seidman EG,. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3 (Suppl. 1): S30-8. (Pubitemid 36395165)
28. Roberts RL, Gearry RB, Barclay ML, Kennedy MA,. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 2007; 7: 312-7. (Pubitemid 47484772)
29. Weinshilboum RM, Raymond FA, Pazmino PA,. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85: 323-33. (Pubitemid 8333694)
30. Sies C, Florkowski C, George P, et al,. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. N Z Med J 2005; 118: U1324.
31. Roberts RL, Barclay ML, Gearry RB, Kennedy MA,. A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clin Chim Acta 2004; 341: 49-53. (Pubitemid 38210313)
32. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML,. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol 2008; 6: 654-60.
33. Dewit O, Starkel P, Roblin X,. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest 2010; 40: 1037-47.
34. Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML,. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur J Gastroenterol Hepatol 2008; 20: 1238-42.
35. Roberts RL, Gearry RB, Bland MV, et al,. Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet Genomics 2008; 18: 434-8. (Pubitemid 351535944)
36. Duley JA, Chocair PR, Florin TH,. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment Pharmacol Ther 2005; 22: 1161-2. (Pubitemid 41779525)
37. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB,. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14. (Pubitemid 46216945)
38. Roberts RL, Gearry RB, Kennedy MA, Barclay ML,. Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease. Pers Med 2008; 5: 233-48. (Pubitemid 351819081)